Zacks Research Issues Positive Forecast for ResMed Earnings

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of ResMed in a research note issued to investors on Tuesday, November 12th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.25 for the quarter, up from their previous estimate of $2.13. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q1 2027 earnings at $2.44 EPS.

RMD has been the subject of a number of other research reports. Royal Bank of Canada lifted their target price on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Wolfe Research restated an “underperform” rating and set a $180.00 target price on shares of ResMed in a report on Wednesday, September 18th. Robert W. Baird boosted their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, Baird R W raised ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $225.70.

ResMed Stock Up 1.4 %

Shares of RMD stock opened at $234.74 on Friday. ResMed has a 12 month low of $147.39 and a 12 month high of $260.49. The stock has a 50 day moving average of $242.83 and a 200-day moving average of $223.55. The firm has a market cap of $34.46 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 1.71 and a beta of 0.69. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the company posted $1.64 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC boosted its position in ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of ResMed in the 3rd quarter worth approximately $34,000. OFI Invest Asset Management purchased a new position in shares of ResMed in the second quarter worth approximately $32,000. Versant Capital Management Inc grew its position in ResMed by 196.7% during the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 120 shares during the period. Finally, Financial Connections Group Inc. purchased a new stake in ResMed during the second quarter valued at approximately $37,000. Institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the completion of the transaction, the chief executive officer now owns 464,169 shares of the company’s stock, valued at approximately $107,645,432.79. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Michael J. Rider sold 882 shares of ResMed stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total transaction of $203,742.00. Following the completion of the sale, the general counsel now owns 10,512 shares of the company’s stock, valued at $2,428,272. This represents a 7.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,056 shares of company stock worth $15,086,020 in the last quarter. 0.71% of the stock is owned by company insiders.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.90%. ResMed’s dividend payout ratio (DPR) is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.